It has been reported that epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) repress tumor lymphangiogenesis in lung cancer via the JAK/STAT3 cascade [38]. The gene discussed is EGFR; the disease is neoplasm.